Rory B. Riggs was the President of Biomatrix, Inc. until the merger with Genzyme Biosurgery in December 2000, a New York Stock Exchange Company, specializing in biomaterial for medical use. Its lead product, Synvisc®, is an important new therapy for osteoarthritis knee pain.

Since being president, Biomatrix has grown from approximately $5 million in revenues to over $70 million in 1999. Mr. Riggs was elected President of the Company on April 1, 1996 and served as the acting Chief Financial Officer from September 1996 to January 1998.He has been a Director of the Company since October 1990.

Since 1991, he has been affiliated with ITIM Corporation, an investment advisory and venture capital firm specializing in technology venture capital. From 1991 to 1994, he was acting President and Chief Executive Officer of RF&P Corporation, a company wholly owned by the Virginia Retirement System. Until 1990, Mr. Riggs was a Managing Director in the Mergers and Acquisitions Department at PaineWebber Incorporated, where he was employed for more than nine years.

He is a graduate of Middlebury College and Columbia University's Graduate School of Business. Mr. Riggs is a member of the Board of Directors of Sparton, Inc., FibroGen, Inc., Chondrogene, Royalty Pharma and Active Life Network.